Attana helps drug developers make better decisions earlier.

The Company’s proprietary biosensor technology enables researchers to study how drugs, antibodies and other biological molecules interact in biologically relevant environments such as blood, plasma, living cells and tissue. Unlike many traditional analytical methods, which rely on purified molecules in simplified laboratory systems, Attana measures molecular interactions in real time and under conditions that more closely resemble human biology. This provides researchers with a deeper understanding of how a drug candidate may behave before entering clinical development.

Understanding More Than Binding

Many analytical techniques can determine whether two molecules bind to each other.

Attana goes beyond this by measuring:

• How fast molecules bind
• How strong they bind
• How long they remain bound

These kinetic characteristics are often critical for understanding a drug’s biological function, efficacy, and safety profile.

By combining kinetic analysis with biologically relevant test environments, Attana can provide insights that may not be visible using traditional approaches.

Why Biological Relevance Matters

Drug development is expensive, time-consuming and associated with a high rate of failure.

Many drug candidates show promising results in early testing but fail later in development because the models used during preclinical research do not fully reflect human biology.

Attana’s technology is designed to generate more biologically relevant data earlier in the development process, helping researchers make more informed decisions regarding which candidates should progress and which may require further evaluation.

Applications

Attana’s technology can be applied across a broad range of life science fields, including:

• Antibody development
• Vaccine development
• Cell-based assays
• Immunogenicity studies
• Infectious diseases
• Biological interaction analysis
• Drug discovery and development
• Translational research

From Technology to Commercialization

Attana’s technology has been validated through scientific collaborations and peer-reviewed publications over many years.

Today, the Company is focused on expanding its commercial footprint through partnerships with CROs, pharmaceutical and biotechnology companies, as well as academic research institutions.

Through instrument sales, rentals, consumables and analytical services, Attana aims to make biologically relevant interaction analysis accessible where critical decisions are made throughout the drug development process.